NASDAQ : MESO
Mesoblast Limited — Key statistics
Healthcare · Biotechnology · Australia
Last price 15.67 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.12B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.92B |
| Enterprise Value | 1.94B |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 26, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 1.30B |
| Shares Change (YoY) | +7.21% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 34.17% |
| Owned by Institutions (%) | 26.10% |
| Float | 830.58M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.41 |
| Forward PS | 10.17 |
| PB Ratio | 3.47 |
| P/TBV Ratio | 969.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 16.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.43 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.58 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -9.86% |
| Return on Assets (ROA) | -4.11% |
| Return on Invested Capital (ROIC) | -4.51% |
| Return on Capital Employed (ROCE) | -7.41% |
| Weighted Average Cost of Capital (WACC) | 9.18% |
| Revenue Per Employee | $1.11M |
| Profits Per Employee | -$532,407 |
| Employee Count | 108 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.95 |
Taxes
| Measure | Value |
|---|
| Income Tax | 613,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -9.90% |
| 50-Day Moving Average | 14.89 |
| 200-Day Moving Average | 15.40 |
| Relative Strength Index (RSI) | 57.39 |
| Average Volume (20 Days) | 297,364 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.27M |
| Short Previous Month | 3.30M |
| Short % of Shares Out | 3.44% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 14.11 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 120.25M |
| Gross Profit | 96.22M |
| Operating Income | -51.25M |
| Pretax Income | -56.89M |
| Net Income | -57.50M |
| EBITDA | -44.61M |
| EBIT | -51.25M |
| Loss Per Share | -$0.45 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 102.91M |
| Total Debt | 127.33M |
| Net Cash | -24.42M |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | 568.41M |
| Book Value Per Share | 0.44 |
| Working Capital | 116.38M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -43.83M |
| Capital Expenditures | -833,000 |
| Depreciation & Amortization | 6.65M |
| Net Borrowing | -5.94M |
| Free Cash Flow | -44.66M |
| FCF Per Share | -$0.03 |
Margins
| Measure | Value |
|---|
| Gross Margin | 80.02% |
| Operating Margin | -42.62% |
| Pretax Margin | -47.31% |
| Profit Margin | -47.82% |
| EBITDA Margin | -37.09% |
| EBIT Margin | -42.62% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.21% |
| Shareholder Yield | -7.21% |
| Earnings Yield | -3.06% |
| FCF Yield | -2.26% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $37.00 |
| Price Target Difference | 151.36% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 62.74% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:2 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 4.13 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |